Search research articles
Contact Us
Filters
Showing results (161-170 of 185) with videos related to
Page
of 19
Sort By:
The Australasian Journal of Dermatology
|
May 14, 2024
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patients
Peter Foley, Patrick D Mahar, Saxon D Smith, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
The British Journal of Dermatology
|
March 21, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials
Andrew Blauvelt, Diamant Thaçi, Kim A Papp, et al.
The British Journal of Dermatology
|
August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study
Joseph F Merola, Albert S Chiou, Emmanuel During, et al.
Frontiers in Neurology
|
September 30, 2021
Study Protocol for the Development of a European eHealth Platform to Improve Quality of Life in Individuals With Huntington's Disease and Their Partners (HD-eHelp Study): A User-Centered Design Approach
Pearl J C van Lonkhuizen, Niko J H Vegt, Eline Meijer, et al.
Lancet (London, England)
|
August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.
Dermatology and Therapy
|
June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
Jonathan I Silverberg, Alan D Irvine, Peter Foley, et al.
Dermatology and Therapy
|
March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Craig Leonardi, Kristian Reich, Peter Foley, et al.
Journal of the American Academy of Dermatology
|
April 5, 2023
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata
Cheng Zhou, Xiumin Yang, Bin Yang, et al.
International Journal of Dermatology
|
January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies
Peter Foley, Michael Freeman, Alan Menter, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 185) with videos related to
Sort By:
Page
of 19
The Australasian Journal of Dermatology
|
May 14, 2024
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patients
Peter Foley, Patrick D Mahar, Saxon D Smith, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
The British Journal of Dermatology
|
March 21, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials
Andrew Blauvelt, Diamant Thaçi, Kim A Papp, et al.
The British Journal of Dermatology
|
August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study
Joseph F Merola, Albert S Chiou, Emmanuel During, et al.
Frontiers in Neurology
|
September 30, 2021
Study Protocol for the Development of a European eHealth Platform to Improve Quality of Life in Individuals With Huntington's Disease and Their Partners (HD-eHelp Study): A User-Centered Design Approach
Pearl J C van Lonkhuizen, Niko J H Vegt, Eline Meijer, et al.
Lancet (London, England)
|
August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.
Dermatology and Therapy
|
June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
Jonathan I Silverberg, Alan D Irvine, Peter Foley, et al.
Dermatology and Therapy
|
March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Craig Leonardi, Kristian Reich, Peter Foley, et al.
Journal of the American Academy of Dermatology
|
April 5, 2023
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata
Cheng Zhou, Xiumin Yang, Bin Yang, et al.
International Journal of Dermatology
|
January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies
Peter Foley, Michael Freeman, Alan Menter, et al.
Page
of 19